- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02154061
Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics (VAX-002)
Systems Biology of Inactivated Influenza Vaccine (IIV) in Healthy Adults With or Without Use of Broad Spectrum Antibiotics
The purpose of the study is to better understand how the use of antibiotics changes micro-organisms in the intestines. The change to micro-organisms in the intestines may change the body's vaccine immune response and alter the effectiveness of the IIV (seasonal flu) vaccine.
In particular, the investigators will be looking at certain markers in blood after vaccination with IIV (seasonal flu vaccine) with or without the use of antibiotics before vaccination.
There will be two randomized groups. Group A will start taking antibiotic by mouth 3 days prior to vaccination and continue taking antibiotics the day of vaccination and one day after vaccination for a total of 5 days. Group B will only receive the IIV (seasonal flu vaccine) and will not take any antibiotics.
The investigators hope to enroll 50 subjects at Emory.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30030
- Emory Vaccine Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Healthy individuals aged 18-40 years.
- Able to understand and give informed consent.
- Women of child-bearing potential (not surgically sterile via tubal ligation, bilateral oophorectomy or hysterectomy or who are not postmenopausal for ≥1 year) must agree to practice adequate contraception that may include, but is not limited to, abstinence, monogamous relationship with vasectomized partner, barrier methods such as condoms, diaphragms, spermicides, intrauterine devices, and licensed hormonal methods for 30 days before and 30 days after TIV vaccination
Exclusion Criteria:
- You received blood product within 3 months of enrolling in the study or a live attenuated vaccine within 4 weeks or inactivated vaccines within 2 weeks.
- You received the 2014-2015 flu vaccine or had a confirmed case of influenza during 2014-2015.
- You received any antibiotics 6 months prior to enrolling in the study or expect to take antibiotics one month after vaccination.
- You received probiotics or prebiotics 3 months prior before enrolling in the study or expect to take one month after vaccination.
- You received proton pump inhibitors, H2 blocker receptors, or antacids 3 months regularly before enrolling in the study or one month after
- You had an allergic response or sensitivity to past vaccinations.
- You have health conditions that weaken your body's ability to fight infections or you are taking drugs like steroids that weaken your body's ability to fight infections.(Some nasal and topical steroids are allowed.).
- You have a chronic medical problem including (but not limited to) insulin dependent diabetes, severe heart disease including arrhythmias, severe lung disease, auto immune diseases and or grade 4 uncontrolled hypertension.
- Chronic neurological conditions such as seizure disorder, Parkinson disease, myasthenia gravis, neuropathy, or histories of encephalopathy, meningitis or ototoxicity.
- Any history of gastrointestinal disease, kidney or liver diseases.
- Alcohol or drug abuse or psychiatric conditions that in the opinion of the investigator would compromise your participation in this trial.
- Pregnant or are breast feeding.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: IIV Flu Vaccine with Antibiotics
This arm will receive antibiotics prior and after IIV administration.
|
This is an FDA approved and tested Inactivated Flu Vaccine.
Andre navn:
This is a standard antibiotic
Andre navn:
This is a standard antibiotic.
This is a standard antibiotic.
Andre navn:
|
Aktiv komparator: IIV Flu Vaccine
This arm will not take antibiotics in conjunction with IIV.
|
This is an FDA approved and tested Inactivated Flu Vaccine.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants With Four Fold Rise in HAI Titers or HAI 1:40 and Above in Each Group at D30
Tidsramme: At day 30
|
Number of participants with four fold rise in HAI titers or HAI 1:40 and above in each group at D30 will be recorded based on immunologic testing of blood samples
|
At day 30
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Luftveisinfeksjoner
- Sykdommer i luftveiene
- Orthomyxoviridae-infeksjoner
- Influensa, menneske
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Enzymhemmere
- Antibakterielle midler
- Proteinsyntesehemmere
- Antiprotozoale midler
- Antiparasittiske midler
- Vancomycin
- Metronidazol
- Neomycin
Andre studie-ID-numre
- IRB00074239
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på IIV Flu Vaccine
-
PATHGlaxoSmithKline; Icahn School of Medicine at Mount Sinai; Duke University; Children... og andre samarbeidspartnereFullførtInfluensa | VaksineForente stater
-
PepTcell LimitedFullført
-
MedImmune LLCAvsluttetRespiratorisk syncytialt virusForente stater, Chile, Sør-Afrika, Canada, Estland, Litauen, Latvia
-
Marshfield Clinic Research FoundationUniversity of Wisconsin, Madison; Centers for Disease Control and PreventionFullførtInfluensa A-virusinfeksjon | Influensa B-virusinfeksjon | Immunrespons på influensavaksineForente stater
-
MedImmune LLCFullførtRespiratorisk syncytialvirus (RSV)Forente stater
-
University of California, San FranciscoAmerican Cancer Society, Inc.; Kaiser PermanenteFullført
-
Green Cross CorporationFullført
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National...Fullført
-
PepTcell LimitedNorwegian Institute of Public Health; University Medical Center Groningen; University of Groningen og andre samarbeidspartnereFullført
-
GlaxoSmithKlineFullført